PCSA Processa Pharmaceuticals, Inc.

BULLISH Impact: 4/10 Insider Cluster (2 insiders)
Horizon weeks Filed Jun 1, 2026 Processed 5d 1h ago
Insider cluster: 2 insiders, $9K total

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders at Processa Pharmaceuticals made open-market purchases totaling ~$9K on May 29, 2026, at $2.57/share. This is a small cluster relative to the $7M market cap (~0.13%), but the fact that both are senior officers buying on the same day at the same price suggests coordinated conviction. The company has a history of insider buying ($33K over 30 days) and a bullish analyst consensus (86% buy), but past cluster reports on PCSA have underperformed at T+20 (-1.24% avg).

Key Financial Metrics

Direction
buying
Total Value
$8.8K
Insiders
2

Actionable Insight

Insider cluster buys at a micro-cap biotech with strong analyst support are a modest positive signal. However, past PCSA cluster reports have negative T+20 alpha (-9.00% vs SPY). Watch for upcoming catalysts (pipeline updates, financing news) that could explain the buying. The small dollar amount limits conviction — treat as a supportive data point, not a standalone trade signal.

Key Facts

  • Chief Administrative Officer Guy Wendy purchased 1,829 shares at $2.57 for $4,701
  • Chief Business & Strategy Officer Lin Patrick purchased 1,582 shares at $2.57 for $4,066
  • Total cluster value: ~$9K, representing ~0.13% of $7M market cap
  • Both trades occurred on the same day (May 29, 2026) at the same price
  • 30-day insider buying totals $33K across 7 transactions
  • Analyst consensus is 86% bullish (6 buy, 1 hold)

Financial Impact

~$9K in insider purchases, ~0.13% of market cap

insider ownershipmarket cap

Risk Factors

  • Micro-cap biotech with $7M market cap — high bankruptcy/dilution risk
  • Past cluster reports on PCSA have underperformed at T+20 (-1.24% avg return)
  • Small absolute dollar amount ($9K) may reflect liquidity constraints, not strong conviction
  • No disclosed catalyst — buying could be routine accumulation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCSA-1780347459824
7 reports for PCSA
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+5▲ +19.60%Mar 31, 2026
Filters
Rows
Reports for PCSA — sortable, filterable
Type Now
Jun 1, 2026
5d ago
Insider Cluster
BULLISH ★ 4/10
awaiting T+20
May 19, 2026
18d ago
Insider Cluster
BULLISH ★ 5/10
awaiting T+20
May 19, 2026
18d ago
Insider Cluster
BULLISH ★ 5/10
awaiting T+20
Apr 30, 2026
5w ago
Insider Cluster
BULLISH ★ 4/10
$2.70 $2.64▼ −2.22%▼ −7.19%$2.52 (−6.67%)
Apr 15, 2026
7w ago
Insider Cluster
BULLISH ★ 5/10
$2.96 $2.56▼ −13.51%▼ −19.56%$2.52 (−14.86%)
Mar 31, 2026
9w ago
Insider Cluster
BULLISH ★ 6/10
$2.53 $2.65▲ +4.95%▼ −4.47%$2.52 (−0.20%)
Mar 31, 2026
9w ago
Insider Cluster
BULLISH ★ 6/10
$2.53 $2.75▲ +8.89%▼ −0.53%$2.52 (−0.20%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (14h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access